Full-Time

Automation Engineer

Merge Labs

Merge Labs

11-50 employees

Develops high-bandwidth brain–computer interfaces

Compensation Overview

$165k - $260k/yr

San Francisco, CA, USA

In Person

Category
Data & Analytics (1)
Required Skills
Machine Learning
Robotics
Data Analysis

Get referred to Merge Labs

See people who can refer or advise you

Requirements
  • Have a background in engineering, robotics, or a similar field with extensive experience in biology, or a background in biology or bioengineering with extensive experience in automation engineering.
  • Have developed high-throughput experimental pipelines involving mammalian cell culture, microscopy, molecular assembly, next-generation sequencing, or protein engineering.
  • Have built unusual setups requiring custom components that were not available off the shelf.
  • Have experience with equipment setup, code writing, biological experiments, and data analysis.
  • Have worked in a fast-paced biotech or techbio environment, ideally a startup.
  • Have high agency to initiate and drive efforts, ideate, and make improvements.
  • Have strong communication skills and enjoy collaborating with researchers.
  • Have developed creative or unexpected solutions to difficult problems.
Responsibilities
  • Partner with program leads and project scientists to define experimental automation needs and key approaches.
  • Apply biological context and experimental understanding to guide automation strategy and execution.
  • Scope, acquire, build, program, and validate instrumentation and software, and teach project teams to use them.
  • Own the quality, reliability, and integrity of data produced by automated pipelines, including defining and integrating appropriate quality-control checkpoints.
  • Collaborate with data science and machine learning engineers to integrate metadata tracking, computational design, and analysis into experimental pipelines.
  • Collaborate with electrical, mechanical, and software engineers to build custom setups.
  • Conceive, design, and validate creative automation strategies to improve experimental throughput.
  • Serve as an integral member of research project teams and contribute insights to project design, execution, and analysis.

Merge Labs develops brain–computer interfaces to connect human brains with computers. Its product focus is high-bandwidth neural implants that read neural signals and transmit data to AI systems and software, enabling bidirectional communication between brain and machine. The implants are designed to work with advances in AI and neural sensing hardware, using a system of implants, interfaces, and software to interpret brain activity and control devices or software. Compared with competitors, Merge Labs aligns with Sam Altman’s vision of human–machine convergence, leveraging OpenAI ventures connections and positioning itself as a Neuralink rival with an emphasis on higher data throughput and scalable AI-assisted interpretation. The company’s goal is to create seamless, high-bandwidth brain–computer communication that enhances human capabilities and enables new ways of interacting with technology.

Company Size

11-50

Company Stage

Seed

Total Funding

$252M

Headquarters

Palo Alto, California

Founded

2025

Get referred to Merge Labs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • January 2026 seed raised $252 million at an $850 million valuation.
  • OpenAI’s largest check signals strategic support and recruiting leverage across AI talent.
  • March 2026 China approved its first brain implant, expanding validation for BCI demand.

What critics are saying

  • March 2026 scrutiny says Merge disclosed no clinical timeline or peer-reviewed human data.
  • Ultrasound-plus-molecules still needs safe gene delivery; failures block any human product.
  • Neuralink’s 2026 mass production and automated surgery outpace Merge’s still-theoretical platform.

What makes Merge Labs unique

  • OpenAI-backed ultrasound BCI targets non-invasive brain access, unlike Neuralink’s implanted electrodes.
  • Sam Altman and Caltech’s Mikhail Shapiro give Merge elite AI-neurotech credibility.
  • OpenAI collaboration on foundation models helps Merge interpret noisy neural signals faster.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

-2%
Florida Today
Feb 14th, 2026
OpenAI invests in Merge Labs at $850M valuation

OpenAI has invested in Merge Labs at an $850 million valuation, according to reports. The investment focuses on scalable AI backends, including AICC technology. Details about the funding round, including the investment amount and other participants, were not disclosed. The partnership appears aimed at advancing AI infrastructure and backend capabilities. Merge Labs is working on developing scalable systems to support AI applications. The company's technology is designed to handle the computational demands of modern AI models. The investment represents OpenAI's continued expansion beyond its core business into supporting technologies and infrastructure for artificial intelligence development.

TechCrunch
Jan 16th, 2026
OpenAI invests in Sam Altman’s brain computer interface startup Merge Labs | TechCrunch

Merge Labs is a “research lab” dedicated to “bridging biological and artificial intelligence to maximize human ability.” OpenAI wrote the largest check in Merge Labs' $250 million seed round at an $850 million valuation.

Bloomberg Law
Jan 15th, 2026
Sam Altman's Merge raises $252M to connect human brains to computers

Merge Labs, co-founded by AI billionaire Sam Altman, has raised $252 million to develop devices connecting human brains to computers. The company aims to seamlessly link people and artificial intelligence to "maximise human ability, agency, and experience". The funding reflects growing Silicon Valley interest in brain-computer interfaces as entrepreneurs anticipate a future where AI becomes so advanced that humans may need to augment their brains to keep pace. Similar to how smartphones provide digital access, experimental brain technology is being designed to streamline human interaction with AI systems. The investment underscores the increasing focus on neurotechnology as a key frontier in the race to integrate artificial intelligence into human capabilities.

Wired
Dec 19th, 2025
Sam Altman’s New Brain Venture, Merge Labs, Will Spin Out of a Nonprofit

Merge Labs, a brain-computer interface startup that seeks to read brain activity using ultrasound, is being spun out of Forest Neurotech, a Los Angeles nonprofit.

Startup Wired
Aug 16th, 2025
Sam Altman Backs Merge Labs' $850M Valuation

Sam Altman, CEO of OpenAI, has invested in Merge Labs, a startup in the brain–computer interface (BCI) sector, now valued at $850 million. Merge Labs focuses on non-invasive BCIs, contrasting with Neuralink's invasive approach. Altman's backing signals confidence in BCI as a transformative technology. The company aims to surpass a $1 billion valuation in the next funding round. Merge Labs emphasizes privacy and aims to make BCI accessible across various sectors.